Echo(1) | $15,000,000 | (Aug 1, 2025)
KredosAi | Undisclosed Amount | (Aug 1, 2025)
Cline | $32,000,000 | (Aug 1, 2025)
Actithera
Norway
- Oslo
- 09/07/2025
- Series A
- $75,500,000
Actithera is a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs). Founded in 2021 by drug discovery innovator Dr. Andreas Goutopoulos, and seed investors M Ventures, and Arkin Bio Ventures II, Actithera applies various molecular design strategies, including covalent-targeting and an isotope-agnostic philosophy to invent RLTs with significant differentiation and larger therapeutic windows. Headquartered in Oslo, Norway, and Cambridge, Massachusetts, Actithera is committed to advancing a differentiated pipeline addressing critical unmet needs in oncology.
- Industry Biotechnology Research
- Website https://actithera.com/
- LinkedIn https://www.linkedin.com/company/actithera/
Related People
Andreas GoutopoulosFounder
United States -
Boston, Massachusetts
Founder of Actithera, developing smarter radiopharmaceuticals to treat cancer more effectively and safely. Focused on turning chemistry and science into better outcomes for patients.
Moonshine AI | Undisclosed Amount | (Aug 1, 2025)
Noma Security | $100,000,000 | (Aug 1, 2025)
Anaconda, Inc. | $150,000,000 | (Aug 1, 2025)
Nebulock | $8,500,000 | (Aug 1, 2025)
MyPrize | $21,000,000 | (Aug 1, 2025)
Safe Security | $70,000,000 | (Aug 1, 2025)
Merso | $3,000,000 | (Aug 1, 2025)
Metaforms | $9,000,000 | (Aug 1, 2025)
Ultromics | $55,000,000 | (Jul 31, 2025)